Published in Oncoimmunology on December 10, 2015
Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape. Nat Rev Clin Oncol (2016) 0.91
The Significance of Epithelial-to-Mesenchymal Transition for Circulating Tumor Cells. Int J Mol Sci (2016) 0.76
Molecular characterization of circulating tumor cells from patients with metastatic breast cancer reflects evolutionary changes in gene expression under the pressure of systemic therapy. Oncotarget (2017) 0.75
The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem (2009) 40.90
Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med (2004) 27.92
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 26.32
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature (2005) 19.13
Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature (2006) 12.13
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol (2004) 10.55
Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol (2014) 10.04
Breast cancer metastasis: markers and models. Nat Rev Cancer (2005) 9.93
The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity (2009) 6.86
Anoikis mechanisms. Curr Opin Cell Biol (2001) 6.36
The FoxO code. Oncogene (2008) 6.22
The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity (2011) 6.00
Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol (2001) 5.80
The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer (1997) 5.01
PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis (2004) 4.33
CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells. Cancer Res (2004) 2.51
Molecular mediators of interactions with extracellular matrix components in metastasis and angiogenesis. Curr Opin Oncol (1994) 2.21
C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br J Cancer (2000) 2.14
Mutations of the human PTEN gene. Hum Mutat (2000) 2.11
Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. Cancer Res (2006) 1.99
Applications of post-translational modifications of FoxO family proteins in biological functions. J Mol Cell Biol (2011) 1.90
Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression. Mol Syst Biol (2008) 1.89
Constitutive expression of E-selectin and vascular cell adhesion molecule-1 on endothelial cells of hematopoietic tissues. Am J Pathol (1996) 1.89
Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat (2009) 1.86
Molecular mechanisms of metastasis in breast cancer--clinical applications. Nat Rev Clin Oncol (2010) 1.83
Circulating tumor cells: not all detected cells are bad and not all bad cells are detected. J Clin Oncol (2011) 1.79
Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res (2009) 1.78
Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett (2009) 1.75
Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR. Breast Cancer Res Treat (2008) 1.74
Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells. J Cell Sci (2001) 1.52
Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res (1989) 1.48
Circulating and disseminated tumor cells. J Clin Oncol (2005) 1.43
Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system. Int J Cancer (2011) 1.38
CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. BMC Cancer (2011) 1.31
H2A.Z functions to regulate progression through the cell cycle. Mol Cell Biol (2006) 1.27
Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecol Oncol (2011) 1.22
Urokinase signaling through its receptor protects against anoikis by increasing BCL-xL expression levels. J Biol Chem (2006) 1.19
Caveolin-1 inhibits cell detachment-induced p53 activation and anoikis by upregulation of insulin-like growth factor-I receptors and signaling. Oncogene (2005) 1.16
Down-regulation of cathepsin-D expression by antisense gene transfer inhibits tumor growth and experimental lung metastasis of human breast cancer cells. Oncogene (2002) 1.14
Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. Expert Opin Biol Ther (2007) 1.12
An important role for the alpha 1,3 fucosyltransferase, FucT-VII, in leukocyte adhesion to E-selectin. Blood (1996) 1.08
Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer. Drugs (2012) 1.06
Correction of RT-qPCR data for genomic DNA-derived signals with ValidPrime. Nucleic Acids Res (2012) 1.03
Inhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator. J Biol Chem (2007) 0.99
Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours. Br J Cancer (2001) 0.99
Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma. Pancreas (2008) 0.99
VEGF-induced endothelial cell migration requires urokinase receptor (uPAR)-dependent integrin redistribution. Cardiovasc Res (2012) 0.98
Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients. BMC Cancer (2010) 0.93
The influence of removal of primary tumor on incidence and phenotype of circulating tumor cells in primary breast cancer. Breast Cancer Res Treat (2011) 0.92
Post-translational modifications of PTEN and their potential therapeutic implications. Curr Cancer Drug Targets (2011) 0.90
PARP-1 controls immunosuppressive function of regulatory T cells by destabilizing Foxp3. PLoS One (2013) 0.90
Consensus genes of the literature to predict breast cancer recurrence. Breast Cancer Res Treat (2007) 0.89
FOXO3: A master switch for regulating tolerance and immunity in dendritic cells. Oncoimmunology (2012) 0.87